CYTH — Cyclo Therapeutics Share Price
0.000.00%
Last trade - 00:00- $33.31m
- $24.06m
- $1.08m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 7 | ||
| Price to Tang. Book | 7 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 30.95 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -419.54% | ||
| Return on Equity | -730.48% | ||
| Operating Margin | -1862.68% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 1.01 | 0.9 | 1.59 | 1.38 | 1.08 | 2.15 | 3.23 | 1.25% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Cyclo Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing transformative therapies for rare and neurological diseases with limited treatment options. The Company’s Trappsol Cyclo is a proprietary formulation of hydroxypropyl beta cyclodextrin. It is an orphan drug designated product in the United States and Europe, and is the subject of four formal clinical trials for Niemann-Pick Disease Type C (NPC) disease. NPC is a rare and fatal autosomal recessive genetic disease resulting in disrupted cholesterol metabolism that impacts the brain, lungs, liver, spleen, and other organs. The Company is also engaged in conducting a Phase 2b clinical trial using Trappsol Cyclo intravenously in early Alzheimer’s disease (NCT05607615) based on encouraging data from an Expanded Access program for Alzheimer’s disease (NCT03624842).
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- October 27th, 2020
- Public Since
- February 27th, 2004
- No. of Shareholders
- 185
- No. of Employees
- 8
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 28,715,740
- Address
- 6714 Nw 16Th Street,, Suite B, GAINESVILLE, 32653
- Web
- https://www.cyclotherapeutics.com/
- Phone
- +1 3864188060
- Contact
- Jeffrey Tate
- Auditors
- WithumSmith Brown PC
Upcoming Events for CYTH
Q2 2024 Cyclo Therapeutics Inc Earnings Release
Similar to CYTH
60 Degrees Pharmaceuticals
NASDAQ Capital Market
Aadi Bioscience
NASDAQ Capital Market
Acasti Pharma
NASDAQ Capital Market
Agriforce Growing Systems
NASDAQ Capital Market
Aptorum
NASDAQ Capital Market
FAQ
What is the Cyclo Therapeutics share price?
As of Today at 19:06 UTC, shares in Cyclo Therapeutics are trading at $1.16. This share price information is delayed by 15 minutes.
How has the Cyclo Therapeutics share price performed this year?
Shares in Cyclo Therapeutics last closed at $1.16 and the price had moved by +63.52% over the past 365 days. In terms of relative price strength the Cyclo Therapeutics share price has outperformed the S&P500 Index by +36.08% over the past year.
What are the analyst and broker recommendations for Cyclo Therapeutics?
The overall consensus recommendation for Cyclo Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Cyclo Therapeutics dividend yield?
Cyclo Therapeutics does not currently pay a dividend.
Does Cyclo Therapeutics pay a dividend?
Cyclo Therapeutics does not currently pay a dividend.
When does Cyclo Therapeutics next pay dividends?
Cyclo Therapeutics does not currently pay a dividend.
How do I buy Cyclo Therapeutics shares?
To buy shares in Cyclo Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Cyclo Therapeutics?
As of the previous close price of $1.16, shares in Cyclo Therapeutics had a market capitalisation of $33.31m.
Where are Cyclo Therapeutics shares listed?
Here are the trading details for Cyclo Therapeutics:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: CYTH
What kind of share is Cyclo Therapeutics?
Based on an overall assessment of its quality, value and momentum Cyclo Therapeutics is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Cyclo Therapeutics share price forecast for 2024?
The analyst consensus target price for shares in Cyclo Therapeutics is $4.00. That is 244.83% above the last closing price of $1.16.
Analysts covering Cyclo Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$1.05 for the next financial year.
What is the trend in the Cyclo Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Cyclo Therapeutics. Over the past six months, its share price has outperformed the S&P500 Index by +4.66%.
As of the last closing price of $1.16, shares in Cyclo Therapeutics were trading -21.25% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Cyclo Therapeutics PE Ratio?
The Cyclo Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.16.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Cyclo Therapeutics?
We do not have data on Cyclo Therapeutics' directors